1,721,417 research outputs found
Efficacy and Safety of Tralokinumab in Real Life: Possible Predictive Rapid Response Factors
No full text: Background: Tralokinumab has been recently approved for the management of moderate-to-severe atopic dermatitis (AD). Despite its effectiveness and safety have been widely reported, there are no studies investigating factors that may affect clinical outcomes. Objective: To evaluate the effectiveness and safety of tralokinumab, also to investigate possible predictive response factors that may affect the time of onset of treatment response. Methods: A monocentric retrospective real-life study was performed enrolling AD patients undergoing treatment with tralokinumab for at least 24 weeks. AD severity was assessed at baseline and at week (W)16, and W24. Similarly, treatment-related adverse events (AEs) were evaluated at each follow-up visit. Results: A total of 57 patients were enrolled. AD severity started to improve at W4, continued to improve at W16 and W24. In our cohort, we found out that gender, age, atopic comorbidities, and previous treatments did not affect treatment outcomes. However, we observed that patients with higher Pruritus-Numerical Rating Scale (≥8), relapsing form of AD, Eczema Area and Severity Index (EASI) ≤24, and Investigator Global Assessment (IGA) ≤3 achieved more frequently EASI75 response at W16. No significant AEs were collected. Conclusions: Our study confirmed the effectiveness and safety of tralokinumab. In particular, a higher pruritus, a relapsing course of the disease, a reduced EASI, a reduced IGA, and a brief duration of the disease seem to be associated with the fastest onset of treatment effectiveness
Dupilumab associated inflammatory arthritis: a literature review
No full text: Dupilumab is a fully human monoclonal antibody that acts by inhibiting the interleukin (IL)-4 receptor subunit α, and hence the IL-4 and IL-13 signalling pathway. Dupilumab treatment has been linked to the onset of T helper (Th)-17 driven inflammatory diseases, including cases of seronegative arthritis and enthesitis. To date, dupilumab-associated inflammatory arthritis (DAIA) represents a relatively not well-known adverse event, initially reported in single cases or case series reports. Indeed, the onset of DAIA may be not promptly recognised, and is probably underestimated. Herein, we reviewed the available English literature regarding arthritis and enthesitis onset during dupilumab treatment for AD, aiming to improve a rapid recognition, and thus a prompt treatment of these diseases
Periungual and subungual pyogenic granuloma following anti-TNF-α therapy: is it the first case?
No full textTumor necrosis factor-alpha (TNF-α) antagonists have advanced treatment of psoriasis and other chronic inflammatory diseases but are not free of adverse effects. Pyogenic granuloma is yet described in literature as a dermatological side effect of multiple drugs such as retinoids, antiretroviral, and antineoplastic drugs but, to the best of our knowledge, it has never been reported among the adverse skin reactions following anti-TNF-α therapy. We report on a 20-year-old Caucasian man with psoriatic arthritis who developed multiple eruptive periungual and subungual pyogenic granulomas following treatment with TNF-α antagonist etanercept.
Skin diseases and visual arts
No full textBackground: in recent years, the medical problems of artists (especially dancers and musicians) have been the subject of research. Notwithstanding, very few data about dermatoses of visual artists are available. Objectives: evaluating the frequency and clinical characteristics of skin diseases in visual artists. Materials and methods: at the Accademia di Belle Arti (School of Arts) in Naples, Italy, a specific questionnaire was administered to students and teachers. Those who reported skin rashes of any kind were clinically evaluated. Results: 231 subjects (84 males, 147 females) aged between 19 and 41 years (mean age 22.5 years) devoted to various artistic activities answered the questionnaire. The largest category was that of the designers represented (36.4%), followed by painters (20.8%). Previous or current dermatoses were found in 120/231 (51.9%) of the subjects. The most frequent pathology was found to be actual chronic hand dermatitis which was diagnosed in 38/120 (31.7%) subjects. The clinical pattern was xerotic and desquamative dermatitis in 32/38 (84.2%), while in 6/38 (15.8%) it was vesicular. Patch testing revealed contact sensitization in two painters with hand dermatitis; they reacted respectively to epoxy resin and to formaldehyde, occupationally relevant allergens. Conclusions: our data seem to indicate that hand dermatitis is a not uncommon occurrence in visual artists and apparently correlated with the profession
- …
